Previous close | 26.00 |
Open | 26.16 |
Bid | 26.21 x 0 |
Ask | 26.22 x 0 |
Day's range | 26.16 - 26.34 |
52-week range | 23.53 - 37.50 |
Volume | |
Avg. volume | 81,572 |
Market cap | 149.482B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.05 |
Earnings date | 30 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | 1.57 (6.04%) |
Ex-dividend date | 09 May 2024 |
1y target est | N/A |
Andrew Baum, the prominent Wall Street drug company analyst will be the pharma firm’s chief strategy and innovation officer.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.